NCT05561985|Unknown
Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease
1 other identifier
I-39110-19-03
Study Type
expanded_access
Target
N/A
Locations
0 countries
Sites
N/A
Timeline
RegisteredSep 2022
Brief Summary
Expanded access use of Itacitinib to treat a single patient with aplastic anemia.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 22, 2022
Completed8 days until next milestone
First Posted
Study publicly available on registry
September 30, 2022
CompletedLast Updated
June 8, 2025
Status Verified
June 1, 2025
First QC Date
September 22, 2022
Last Update Submit
June 6, 2025
Conditions
Keywords
STAT1 GOF disease
Interventions
ItacitinibDRUG
Also known as: INCB039110
Eligibility Criteria
Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Interventions
itacitinibINCB039110
Study Officials
- PRINCIPAL INVESTIGATOR
Lisa Forbes Satter, MD
Baylor College of Medicine - Texas Children's Hospital
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 22, 2022
First Posted
September 30, 2022
Last Updated
June 8, 2025
Record last verified: 2025-06